Day 1 :
University of Chicago Pritzker School of Medicine, USA
Keynote: Resisting response evaluation criteria in solid tumors: New methods of assessing tumour response to therapy
Time : 09:30-10:10
Introduction: Traditional chemotherapy is cytotoxic in nature and acts primarily by eliminating neoplastic cells. Change in tumor size, which is an indicator of change in the number of neoplastic cells, evolved into the radiologic biomarker of treatment response. Over the last decade, dramatic advances in understanding the genetics and molecular biology of tumors have revolutionized therapy for many neoplasms. Molecular targeted therapy and immunotherapy have led to new, individualized tumor therapies. These interfere with signaling pathways and thereby inhibit cell grown but do not necessarily lead to cell death, unlike cytotoxic drugs. With targeted agents, lack of progression may be associated with positive improvement in outcome, even in the absence of major shrinkage of tumors. Oncologists have become interested in the length of time that cancer does not grow or metastasize. Progression-free survival has become the preferred endpoint for many cancer therapy trials. In this presentation, new criteria for imaging tumor response in the era of personalized medicine are presented and guidelines for learning when it is appropriate to resist using RECIST are presented.
Conventional anatomic criteria:
Evolving imaging biomarkers:
Conclusion: RECIST 1.1 is the mainstay of evaluating tumor response to therapy for most cancers
These criteria depend primarily on assessing changes in tumor dimensions but they do not reflect other morphologic, functional, or metabolic changes that may occur with novel chemotherapy, targeted or immunotherapy. It is important for radiologists to integrate new concepts in the evaluation of tumor response in
Queen’s University, Canada
Myron R Szewczuk is Full Professor of Immunology and Medicine, Queen’s University, Kingston, Ontario Canada. His research has focused on the role of glycosylation in receptor activation with a particular focus of Toll-like, neurotrophin Trk, EGFR and insulin receptors. A novel receptor-signalling platform was discovered, and its targeted translation in multistage tumorigenesis. He is now in the development of engineered drug delivery systems.
Conventional chemotherapies targeting tumor suffer from limitations such as poor aqueous solubility, causing elevated toxicity, lack of selectivity toward cancer cells, and multiple drug resistance against treatments. This presentation will discuss the development of ‘smart’ drug delivery systems for the treatment of cancer. Here, we engineered drug carrier systems with three delivery strategies that allow drug carriers to initiate the enhanced permeability and retention (EPR) effects at tumor sites, actively and specifically targeting cancer cells with prolonged circulation time and controlled drug release, and thirdly, stimuli-responsive drug carriers. Firstly, the metronomic therapy of a slow-released oseltamivir phosphate (OP) encapsulated in a biodegradable poly (lactic-co-glycolic acid) (PLGA-OP) cylinder implanted at the tumor site without the need for repeated drug administration impeded tumor neovascularization, growth, and metastasis in heterotopic xenografts of tumors growing in a mouse model of human pancreatic cancer. Secondly, OP-conjugated polymeric micelles prepared by RAFT living radical polymerization specifically targeted and halted tumor growth followed with the cancer cell internalization of the micelle loaded with a cytotoxic chemotherapeutic. Thirdly, a pH-responsive, active targeting delivery system was designed using folic acid functionalized amphiphilic alternating copolymer poly(styrene-alt-maleic anhydride) (FA-DABA-SMA) via a biodegradable linker 2,4-diaminobutyric acid (DABA). This latter study revealed that the novel interactions between the modified FA-DABA-SMA polymers with the cells could lead to enhanced hydrophobic drug delivery efficiency as a probe for cancer chemotherapeutics. Lastly, we fabricated and characterized Pickering water-in-oil emulsions as a reservoir delivery platform for the sustained release of low molecular weight hydrophilic therapeutic molecules disabling human pancreatic cancer cell survival.
University of Victoria, Canada
Time : 11:10-11:50
B Devika Chithrani did her doctoral and postdoctoral studies at the University of Toronto, Canada. She supported by many prestigious scholarships and awards throughout her academic carrier. She is the director of nanoscience and technology development laboratory at the University of Victoria. She leverages nanotechnology to create innovations that advance the care of cancer patients. Her work is featured on the cover of journals and her publications in reputed journals have received close to 7500 citations in few years. She has earned a strong international reputation for her innovative research through her many review articles, book chapters, and invited presentations. She is an associate editor of many nanotechnology-based journals. Her passion is to develop smart nanomaterials to improve existing cancer therapeutics.
The goal of NP-based platforms will be the targeted delivery of therapy to tumors with minimal side effects. Optimizing the interface between NPs and biological environment at various levels should be discussed for improving delivery of NPs to the target tumour area. Successful delivery of NPs into tumor depends on efficiency of crossing few boundaries effectively as discussed in the previous section: NPs needs to be functionalized for circulation through the blood vessels until it reaches tumor vasculature where NPs can make use of the leakiness of the vasculature to enter tumor tissue, once NPs enter the tumor tissue, their transport through the tumor matrix depends on their size and surface properties, and c) Once these NPs reaches single cells within the tumor matrix, their uptake depends on size, shape, and surface properties of NPs. In this presentation, will discuss a how we can optmize interface between nanotechnology and medicine using gold nanoparticle as a model system. Will also share the results of a recent study where optimaization at all three infefaces (monolayer, tissue, in vivo delivery) resulted in 12 to 15% injected NP dose within the tumor. Hence, We will unveil a road-map to clinical translation of GNPs through ovecoming barriers at many diffrent interfaces.
New York Medical College,USA
Yoshiaki Omura received Oncological Residency training at Cancer Institute of Columbia University & Doctor of Science Degree through research on Pharmaco-Electro-Physiology of Single Cardiac Cells in-vivo and in-vitro from Columbia University. He researched EMF Resonance phenomenon between 2 identical molecules for non-invasive detection of various molecules & various cancers, at Graduate Experimental Physics Dept., Columbia University, for which he received U.S. Patent “Bi-Digital O-Ring Test for non-invasive diagnosis & treatment”. He published over 290 original research articles, many chapters, & 9 books. He is currently Adjunct Prof. of Family & Community Medicine, New York Medical College; President & Prof. of International College of Acupuncture & Electro-Therapeutics, NY; Editor in Chief, Acupuncture & Electro-Therapeutics Research, International Journal of Integrated Medicine. Formerly, he was Director of Medical Research for Heart Disease Research Foundation and he was also Adjunct Prof. or Visiting Prof. in Universities in USA, France, Italy, Ukraine, Japan, Korea, & China.
Cancer can be detected non-invasively and rapidly by the following 5 methods Using organ representation area of the different parts of the face including eyebrows, all of the nose, upper & lower lips. The author found the visible and invisible appearance of cancer-related changes. Some of the visible changes are deep crease formation, protrusion, discoloration, change of the color of the hair and eyebrows to white color or disappearance of the hair. Using Mouth, Hand & Foot Writing Form completed by the patient which takes anywhere from 5~10minutes, we can make a diagnosis of cancer without having any information about the patient. Using rapidly changing QRS-complex of ECG, cancer can be identified rapidly and when QRS-complex is more than 1.2 mV we can often detect cancer parameters. 4) Normally when Thymus gland immune system is very weak, organ representation area of the back of each hand becomes less negative. When thymus functions are normal, Thymosin α1 & Thymosin β4 are usually anywhere between 5~50ng. Values lower than 1 ng indicate an immune deficiency. Using urine of less than 1cc, we can detect the presence or absence of cancer in less than 30sec. and identify the type of cancer it will take additional 5-10min for each different cancer. Since we often find multiple cancers, each additional cancer requires the same additional time duration. By utilizing these methods cancer can be detected long before standard hospital laboratory tests can detect cancer. When we identify cancer with our methods, we recommend the patient to be examined by standard hospital laboratory tests at least twice a year. Some typical examples of these methods will be presented. Concerning treatment, we found every beneficial substance has an optimal dose and if we treat the patient with more than 2 or 3 times the optimal dose, the effect on the patient becomes toxic instead of beneficial. We found the optimal dose of vitamin D3 has 10 unique beneficial effects including very effective anti-cancer effects and effective urinary excretion of the virus, bacteria, fungus, and very significant increasing acetylcholine increasing effect in the brain and other parts of the body which improves not only memory and brain function but also improves neuro-muscular problems. Although optimal dose of vitamin D3 has the best anti-cancer effect by lowering cancer parameters such as Integrin α5β1 which often reduces from over 2500ng to low levels of 1pg. But when we combine an optimal dose of vitamin D3 immediately followed by an optimal dose of white fresh Dragon fruit, which contains high concentrations of zinc, Integrin α5β1 can go down to lowest values of 1/1000 pg and we obtained lowest amounts of 8-OH-dG which is proportional to DNA mutation. Thus, we have discovered methods of lowering cancer markers to the lowest values. When this condition is reached by adding the following 2 procedures, the author previously discovered, we can often stop cancer activity completely including hopelessly advanced terminal cancer patients. By application of Selective Drug Uptake Enhancement Method. By stimulation of Thymus gland representation area on the back of each hand as well as on the back of each foot, which was discovered by the author in 2017.